As of 2025-05-29, the Intrinsic Value of Qualigen Therapeutics Inc (QLGN) is -53.07 USD. This QLGN valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.65 USD, the upside of Qualigen Therapeutics Inc is -1,553.84%.
Based on its market price of 3.65 USD and our intrinsic valuation, Qualigen Therapeutics Inc (QLGN) is overvalued by 1,553.84%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -53.07 - -53.07 | -53.07 | -1,553.84% |
| P/E | (11.67) - (153.89) | (84.37) | -2411.6% |
| DDM - Stable | (81.52) - (363.45) | (222.49) | -6195.6% |
| DDM - Multi | (128.89) - (462.13) | (203.32) | -5670.5% |
| Market Cap (mil) | 2.70 |
| Beta | 2.19 |
| Outstanding shares (mil) | 0.74 |
| Enterprise Value (mil) | 3.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.87% |
| Cost of Debt | 5.00% |
| WACC | 8.32% |